ICH-USFDA Guidance: Non-Interventional Studies and Post-Approval Safety Reporting

This blog summarizes two important regulatory guidances from the U.S. Food and Drug Administration (FDA) that support pharmacovigilance and real-world evidence generation:

• M14: General Principles for Planning, Designing, Analyzing, and Reporting Non-Interventional Studies

• E2D(R1): Post-approval Safety Data – Definitions and Standards for Management and Reporting of Individual Case Safety Reports

Together, these guidances provide a framework for how pharmaceutical companies generate real-world evidence and manage post-marketing safety information for medicinal products.

Guidance: M14: Principles for Non-Interventional Studies

The M14 guidance outlines the key principles for planning, designing, analyzing, and reporting non-interventional studies (NIS) that utilize real-world data to evaluate the safety and effectiveness of medicines.

Non-interventional studies assess medicinal products in routine clinical practice, meaning that treatment decisions are made independently of a study protocol. Instead of assigning treatments as in clinical trials, these studies observe how medicines are used in real healthcare settings.

Real-world data used in such studies may come from sources such as electronic health records, patient registries, insurance claims databases, or healthcare administrative datasets.

The guidance emphasizes that careful methodological planning is essential when using real-world data. Researchers should clearly define study objectives, select appropriate patient populations, and ensure that data sources are reliable and relevant to the research question.

Study designs may include observational cohort studies, case-control studies, or other epidemiological approaches. Because treatments are not randomly assigned, appropriate statistical methods are necessary to reduce bias and confounding.

Transparent reporting is also critical. Study reports should clearly describe the study design, data sources, analysis methods, and limitations so that regulators and other stakeholders can properly interpret the results.

Guidance: E2D(R1): Post-Approval Safety Data and Individual Case Safety Reports

The E2D(R1) guidance provides internationally harmonized definitions and standards for managing post-approval safety data and reporting Individual Case Safety Reports (ICSRs). Developed through the International Council for Harmonisation (ICH), this guidance helps ensure consistent pharmacovigilance practices across regulatory regions.

The guidance defines several key pharmacovigilance terms. An adverse event (AE) refers to any unfavorable medical occurrence in a patient who has received a medicinal product, regardless of whether a causal relationship is established. An adverse drug reaction (ADR) refers to a harmful and unintended response to a medicinal product where a causal relationship is at least reasonably possible.

Serious adverse events include outcomes such as death, life-threatening conditions, hospitalization, disability, or congenital anomalies. Adverse reactions are considered unexpected if they are not consistent with information provided in the product labeling. 64184517fnl E2D(R1) Postapprova…

A key component of post-marketing safety monitoring is the Individual Case Safety Report (ICSR). An ICSR is a structured report describing an adverse event occurring in a specific patient. For a report to qualify as an ICSR, it must include four minimum elements: an identifiable patient, an identifiable reporter, a suspected medicinal product, and at least one adverse event or observation.

Safety reports may originate from several sources, including healthcare professionals, consumers, scientific literature, digital platforms, non-interventional studies, patient support programs, or regulatory authorities. Marketing authorization holders must review these sources to identify reportable safety information.

Serious and unexpected adverse events generally require expedited reporting, typically within 15 calendar days after the company becomes aware of the case.

The guidance also emphasizes good case management practices, including accurate documentation, medical evaluation of cases, follow-up for additional information, duplicate case detection, and electronic reporting using the ICH E2B reporting format.

By following these frameworks, pharmaceutical companies can generate reliable evidence and maintain effective monitoring of the safety of medicines used in clinical practice.